last
decad
seen
tremend
growth
studi
attempt
take
gene
therapi
cancer
clinic
arena
major
object
introduc
genet
materi
cancer
cell
intent
sensit
chemoand
radiat
therapi
number
strategi
reach
phase
ii
clinic
trial
show
promis
addit
use
molecular
tool
engin
major
thrust
field
imag
affect
cancer
cell
fate
therapi
exampl
positron
emiss
tomographi
pet
magnet
reson
imag
mri
occasion
achiev
convers
imag
probe
therapeut
protein
result
imag
featur
sometim
coexpress
protein
accomplish
chapter
review
statu
cancer
gene
therapi
field
focu
new
technolog
direct
exist
problem
highlight
discuss
area
gene
therapi
applic
radiat
therapi
imag
vector
vehicl
carri
dna
cell
valeri
one
overrid
technic
difficulti
share
gene
therapi
vector
rel
ineffici
deliveri
dna
tumor
tumor
cell
need
affect
cancer
would
recur
viru
vector
includ
adenoviru
adv
adenoassoci
viru
aav
retroviru
rv
tradit
vector
choic
introduc
genet
materi
eg
suppressor
gene
dominantneg
gene
suicid
gene
cancer
cell
make
sensit
chemoand
radiat
therapi
virus
evolv
highli
effect
mechan
infect
cell
capit
howev
vector
pro
con
tabl
molecular
engin
virus
alter
accommod
therapeut
gene
time
allow
effici
growth
safe
handl
signific
problem
use
viral
vector
cancer
gene
therapi
product
qualiti
control
issu
safeti
cost
associ
obtain
clinic
grade
prepar
suitabl
human
use
term
effici
deliveri
adv
remain
effect
viral
vector
abil
obtain
high
titer
higher
multipl
infect
moi
ie
viru
per
cell
ratio
viral
vector
rel
eas
larg
quantiti
viru
isol
purifi
tabl
retroviru
recent
lentiviru
lv
remain
promis
vector
howev
wherea
adv
typic
integr
genom
infect
cell
rv
lv
integr
potenti
could
safeti
concern
due
possibl
critic
cellular
gene
inactiv
insert
viru
advantag
properti
adv
consid
suitabl
vector
cancer
therapi
rv
lv
howev
effici
deliveri
virus
tumor
still
major
problem
despit
virus
abil
infect
cell
cultur
high
level
effect
deliveri
viru
mean
physic
chemic
within
tumor
bed
remain
major
technic
hurdl
freytag
et
al
penetr
adv
within
tissu
rare
exce
volum
larger
cubic
centimet
thu
limit
potenti
success
small
tumor
aav
also
consid
vector
cancer
therapi
li
et
al
howev
even
though
aav
supposedli
integr
specif
chromosom
site
potenti
avoid
mutagenesi
product
issu
rel
low
express
level
therapeut
gene
aav
vector
share
rv
lv
tabl
studi
attempt
direct
inject
dna
tumor
either
alon
complex
lipid
introduc
dna
rna
directli
tumor
limit
immun
respons
sometim
elicit
viral
prepar
administ
howev
effici
lipiddna
enter
cell
tumor
remain
problem
rel
nonspecif
cellular
uptak
lipiddna
complex
attempt
incorpor
molecul
lipid
bilay
bind
cell
surfac
receptor
improv
cell
specif
investig
differenti
effect
seen
vitro
gener
duplic
vivo
along
line
recent
nanoparticl
also
consid
vector
deliv
therapeut
gene
ad
benefit
nanoparticl
also
imag
nie
et
al
adenoviru
rel
larg
dna
viru
infect
varieti
epitheli
endotheli
cell
express
coxsackieadenoviru
receptor
integrin
receptor
valeri
rel
larg
therapeut
gene
transfer
adv
firstgener
virus
harbor
dna
insert
wherea
gut
adv
abl
harbor
dna
abil
adv
addit
rel
eas
viru
propag
purifi
larg
quantiti
made
adv
attract
vector
choic
cancer
gene
therapi
term
target
therapeut
adv
specif
cell
number
clever
approach
devis
includ
alter
viral
penton
protein
necessari
infect
alter
propens
infect
cancer
cell
normal
cell
glasgow
et
al
engin
adv
vector
remain
biolog
effici
costeffect
viral
cancer
gene
therapi
vector
aav
rel
small
dna
viru
integr
specif
chromosom
site
chromosom
infect
divid
nondivid
cell
transduc
broad
rang
tissu
vivo
initi
longterm
gene
express
tissu
li
et
al
furthermor
wildtyp
aav
caus
known
diseas
stimul
cellmedi
immun
respons
order
aav
propag
requir
helper
viru
adv
rel
small
genom
size
allow
smaller
therapeut
gene
transfer
similar
adv
attempt
chang
cell
tropism
aav
infect
success
vitro
approach
yet
fulli
test
vivo
thu
aav
similar
rv
lv
properti
gene
therapi
vector
may
signific
mutagenesi
threat
two
virus
tabl
engin
mous
leukemia
retroviru
first
viral
vector
develop
cancer
gene
therapi
culver
et
al
retrovirus
stabli
integr
randomli
genom
infect
cell
thu
would
potenti
safeti
issu
anoth
major
shortcom
rv
vector
cancer
gene
therapi
rel
low
express
level
compar
adenoviru
typic
lv
use
gene
therapi
human
retroviru
deriv
human
immunodefici
viru
highli
effici
infect
cell
contrast
mous
retroviru
human
lv
infect
nondivid
cell
addit
divid
cell
make
vector
attract
somat
cell
gene
therapi
vitro
work
howev
cancer
gene
therapi
lv
may
advantag
sinc
infect
indiscrimin
wherea
rv
infect
divid
cancer
cell
rv
lv
vector
attract
featur
ideal
human
cancer
gene
therapi
discoveri
posit
charg
lipid
could
use
introduc
dna
cell
vitro
open
possibl
use
lipiddna
complex
direct
intratumor
inject
lipiddna
complex
effici
transfect
cell
vitro
howev
low
yield
cellular
uptak
vivo
remain
problem
advent
strategi
gene
transfer
silenc
technic
consider
use
synthes
antisens
oligonucleotid
rna
interfer
see
manipul
gene
express
lipid
vector
probabl
promis
vector
long
run
sinc
viral
vector
like
continu
product
safeti
issu
adequ
address
result
high
product
cost
entir
manmad
dnarna
lipid
need
human
use
would
provid
excel
scaleup
capabl
qualiti
control
increas
safeti
similar
manufactur
small
molecul
cancer
drug
howev
effici
specif
lipid
deliv
dna
tumor
need
improv
nanoparticl
made
chemic
synthes
highli
structur
macromolecul
abl
entrap
drug
therapeut
dna
rna
andor
agent
imag
show
enorm
futur
potenti
nie
et
al
complet
synthet
nanoparticl
vector
dna
rna
gene
therapi
like
way
futur
cancer
gene
therapi
studi
use
viral
vector
particular
adv
deliv
therapeut
dna
tumor
cell
mani
clever
way
devis
numer
cellular
process
explor
target
enhanc
kill
cancer
cell
vitro
exampl
increas
apoptosi
mani
time
strategi
also
shown
efficaci
anim
tumor
model
herein
signific
studi
concept
discuss
improv
transmiss
spread
adv
within
tumor
design
magic
bullet
cancer
cell
oncolyt
adv
develop
bischoff
et
al
basic
idea
adv
replic
cancer
cell
normal
cell
due
mutat
specif
viral
gene
render
adv
replic
depend
mutant
abnorm
condit
found
half
cancer
infect
mutant
cancer
cell
subsequ
lyse
break
open
cell
releas
new
adv
avail
infect
addit
cancer
cell
thu
name
oncolyt
tumor
suppressor
initi
believ
make
decis
whether
replic
occur
notmut
allow
oncolyt
viru
replic
wherea
wild
type
sinc
normal
somat
cell
express
wildtyp
would
allow
adv
replic
thu
would
spare
howev
turn
process
modul
cell
cycl
checkpoint
includ
arf
may
also
play
import
role
whether
oncolyt
adv
replic
nevertheless
oncolyt
adv
show
posit
initi
clinic
result
magic
bullet
cancer
howev
oncolyt
viru
concept
remain
highli
attract
strategi
cancer
therapi
gener
sinc
would
seek
cancer
cell
destroy
wherea
normal
cell
would
left
unharm
alemani
addit
permut
origin
oncolyt
viru
idea
propos
test
use
varieti
differ
virus
also
includ
therapeut
gene
tumor
suppressor
suicid
gene
see
produc
potenti
multiprong
therapeut
effect
rna
interfer
rnai
highli
conserv
mechan
small
nonproteincod
rna
molecul
interfer
modul
gene
express
although
rnai
repres
one
function
varieti
small
noncod
rna
molecul
receiv
attent
larg
util
basic
research
tool
silenc
express
specif
gene
zamor
haley
moreov
potenc
high
specif
rnai
emerg
promis
new
therapeut
strategi
reduc
elimin
gene
express
anim
inde
rnai
alreadi
undergo
human
clinic
trial
includ
pioneer
work
treat
macular
degener
respiratori
syncyti
viral
infect
bumcrot
et
al
rnai
catalyz
rna
molecul
approxim
nucleotid
length
origin
exogen
endogen
sourc
kim
fig
incred
specif
inher
rnai
deriv
basic
mechan
action
wherebi
small
interf
rna
sirna
molecul
hybrid
specif
cognat
messeng
rna
result
degrad
mrna
endogen
silenc
mechan
found
multicellular
organ
exploit
achiev
silenc
specif
gene
introduct
synthet
sirna
molecul
predesign
hybrid
target
gene
fig
sirna
molecul
also
hold
signific
promis
gene
therapi
approach
recent
review
sirna
biogenesi
mechan
inhibit
rnai
see
liu
et
al
addit
extracellularli
introduc
sirna
exist
anoth
class
small
rna
molecul
term
microrna
mirna
encod
genom
organ
mirna
repres
abund
class
natur
occur
small
rna
differ
sirna
origin
unlik
sirna
mirna
initi
transcrib
part
much
longer
primari
transcript
process
liber
hairpin
precursor
nucleotid
nucleu
liu
et
al
precursor
export
cytoplasm
process
enzym
dicer
produc
rna
duplex
thu
point
mirna
sirna
similar
enter
common
pathway
one
strand
rna
duplex
becom
incorpor
protein
complex
known
risc
rnainduc
silenc
complex
function
risc
guid
interact
sirna
mirna
mrna
catalyz
either
degrad
mrna
inhibit
translat
fig
hutvagn
simard
basic
mechan
rnai
uncov
clear
sirna
could
introduc
cell
silenc
express
specif
gene
inde
synthet
sirna
commerci
avail
silenc
human
gene
anoth
strategi
manipul
mirna
alter
gene
express
estim
human
genom
encod
hundr
form
mirna
regul
express
larg
number
proteincod
gene
review
see
ambro
inde
mirna
found
control
wide
rang
biolog
process
includ
develop
metabol
cell
growth
cell
death
cell
fate
determin
ambro
alter
express
mirna
associ
human
diseas
includ
cancer
hammond
one
strategi
inhibit
function
mirna
use
antagomir
hybrid
mirna
prevent
incorpor
risc
matt
et
al
fig
use
strategi
possibl
increas
express
specif
gene
matt
et
al
rnai
potenti
sever
major
advantag
compar
tradit
therapeut
first
sirna
design
target
gene
unparallel
specif
second
protein
inhibit
includ
protein
amen
tradit
drug
inhibit
structur
protein
etc
result
increas
number
proofofprincipl
studi
conduct
deliv
sirna
mice
exampl
includ
system
administr
sirna
mous
model
hypercholesterolemia
rheumatoid
arthriti
recent
review
see
bumcrot
et
al
along
line
short
hairpin
rna
shrna
express
viral
vector
rv
lv
shown
inhibit
specif
gene
express
provid
stabl
inhibit
gene
express
transient
transfect
sirna
sirna
deliv
system
anim
degrad
rapidli
kim
rossi
make
feasibl
deliv
sirna
help
vector
eg
lipid
nanoparticl
success
anim
studi
fuel
applic
rnai
use
primat
human
test
treat
variou
diseas
dykxhoorn
lieberman
exampl
shown
local
deliveri
sirna
lung
abl
protect
primat
sever
acut
respiratori
syndrom
sar
coronaviru
li
et
al
furthermor
human
studi
shown
deliveri
uncomplex
nake
sirna
success
treatment
variou
human
diseas
dykxhoorn
lieberman
survivin
telomeras
gene
critic
involv
cancer
growth
regul
target
sirna
vitro
vivo
encourag
result
martin
caplen
putral
et
al
altogeth
signific
progress
made
appli
rnai
therapeut
strategi
rel
short
period
sinc
initi
discoveri
undoubtedli
biggest
challeng
success
applic
rnaibas
therapi
remain
deliveri
like
approach
howev
varieti
strategi
explor
address
problem
kim
rossi
clear
potenti
rnaibas
technolog
treatment
cancer
human
diseas
yet
fulli
achiev
introduct
tumor
suppressor
gene
cancer
cell
slow
growth
result
manag
cancer
least
underli
hypothesi
suppressor
gene
like
affect
normal
cell
sinc
type
cell
bodi
alreadi
growth
suppress
one
first
tumor
suppressor
consid
gene
therapi
gene
roth
introduct
tumor
suppressor
gene
tumor
cell
result
complet
halt
prolifer
increas
apoptosi
howev
clinic
trial
disappoint
primarili
insuffici
administr
viru
tumor
roth
number
differ
permut
approach
attempt
gener
strategi
success
primarili
underli
problem
poor
penetr
vector
tumor
bed
ternovoi
et
al
express
tumor
suppressor
gene
retinoblastoma
pten
therapeut
protein
aim
slow
tumor
growth
pursu
clinic
trial
mainli
similar
reason
move
forward
hand
signific
advanc
made
melanoma
differentiationassoci
perhap
due
molecul
multitud
attract
properti
tumor
suppressor
show
bystand
effect
specif
cancer
cell
fisher
inou
et
al
addit
cancer
cell
express
also
sensit
chemoand
radiat
therapi
fisher
phase
trial
patient
solid
tumor
show
clinic
biolog
effect
tong
et
al
suggest
might
excel
therapeut
molecul
might
benefit
patient
cancer
suicid
gene
concept
base
express
heterolog
gene
code
enzym
convert
inact
prodrug
activ
drug
combin
radiat
result
increas
cell
kill
valeri
ideal
maximum
effect
suicid
gene
exist
target
cell
first
suicid
gene
herp
simplex
thymidin
kinas
hsvtk
gene
use
combin
antiherp
drug
ganciclovir
culver
et
al
improv
util
acyclovir
drug
current
use
treat
herpesassoci
enceph
children
mutant
hsvtk
rosenberg
et
al
valeri
et
al
bacteri
yeast
cytosin
deaminas
kievit
et
al
trinh
et
al
also
shown
anim
model
effect
radiosensit
ad
benefit
suicid
geneprodrug
concept
fact
activ
toxic
drug
spread
adjac
tumor
cell
gap
junction
cellular
releas
increas
toxic
surround
cell
improv
therapeut
effect
number
phase
ii
clinic
studi
conduct
suicid
gene
approach
focu
combin
suicid
gene
concept
radiat
therapi
see
enhanc
tumor
toxic
use
cell
defens
system
express
variou
cytokin
immunomodulatori
protein
investig
potenti
strategi
radiosensit
express
variou
vector
combin
modal
combin
cytokin
gene
therapi
radiat
chemotherapi
shown
promis
clinic
set
advanc
studi
base
tumor
necrosi
combin
radiat
kufe
weichselbaum
potent
antitumor
antiangiogenesi
activ
synerg
radiat
therapi
develop
adv
express
control
radiationinduc
promot
limit
toxic
irradi
area
case
direct
inject
tumor
other
studi
combin
radiat
therapi
immunotherapi
preclin
model
chiang
et
al
tsai
et
al
howev
studi
similar
involv
immunotherapybas
approach
combin
radiotherapi
move
forward
clinic
trial
number
clinic
trial
aim
determin
safeti
andor
efficaci
cancer
gene
therapi
continu
grow
discuss
herein
limit
trial
focu
treatment
combin
radiat
therapi
adenoviru
express
cytokin
control
radiationinduc
promot
mundt
et
al
phase
trial
complet
metastat
solid
tumor
treatment
well
toler
minor
toxic
dose
high
particl
unit
pu
correspond
approxim
infecti
unit
iu
control
prospect
clinic
trial
initi
patient
local
advanc
pancreat
cancer
better
defin
therapeut
contribut
chang
et
al
sever
phase
iii
trial
use
multiprong
approach
combin
two
suicid
geneprodrug
approach
hsvtkgcv
condit
replic
adv
imageguid
radiat
therapi
imrt
conduct
includ
one
patient
intermedi
highrisk
prostat
cancer
recent
complet
freytag
et
al
doselimit
toxic
treatmentrel
seriou
advers
event
trial
rel
previou
trial
use
firstgener
adv
increas
hematolog
hepat
gastrointestin
genitourinari
toxic
posttreat
prostat
biopsi
yield
provoc
preliminari
result
result
categor
prognost
risk
treatment
effect
observ
intermediaterisk
group
patient
posit
cancer
last
biopsi
improv
adv
vector
express
yeast
cd
mutant
hsvtk
better
util
prodrug
oncolyt
adv
backbon
combin
coexpress
adv
death
protein
facilit
cell
lysi
improv
adv
spread
preclin
pancreat
cancer
anim
model
substrat
hsvtk
label
f
f
guanin
ffhbg
use
probe
pet
infect
tumor
cell
imag
freytag
et
al
adv
readili
detect
pancrea
tissu
suggest
adv
combin
radiotherapi
pancrea
without
result
excess
system
toxic
current
novel
adv
undergo
phase
trial
patient
pancreat
cancer
studi
test
feasibl
use
f
fluoroganciclovir
fgcv
probe
imag
hsvtkexpress
cell
tissu
preclin
anim
model
use
micropet
similar
posit
result
lu
et
al
time
therapeut
protein
imag
case
second
protein
need
express
imag
ideal
clinic
suitabl
imag
technolog
pet
mri
vector
studi
usual
limit
adv
viral
vector
abl
harbor
larger
dna
insert
one
exampl
strategi
use
doubl
suicid
gene
prodrug
condit
replic
adv
mention
coexpress
human
iodid
symport
hni
gene
report
singlephoton
emiss
comput
tomographi
spect
siddiqui
et
al
hni
sequest
probe
sodium
pertechnet
na
tco
affect
tissu
case
prostat
siddiqui
et
al
na
tco
us
food
drug
administr
fda
approv
diagnost
imag
probe
found
spect
imag
readili
detect
day
administ
adv
current
adv
undergo
clinic
test
abil
imag
express
therapeut
gene
increas
inform
gain
clinic
trial
tremend
futur
novel
way
imag
tumor
pet
mri
clinic
util
imag
technolog
patient
undergo
gene
therapi
like
continu
facilit
assess
vector
penetr
treatment
efficaci
idea
use
cancer
gene
therapi
improv
chemoand
radiotherapi
initi
excit
promis
result
gener
variou
anim
tumor
model
howev
clinic
trial
far
shown
littl
impact
patient
surviv
rang
differ
type
cancer
almost
year
later
field
still
tri
deal
technic
issu
regardless
therapeut
strategi
effici
deliveri
therapeut
dna
rna
tumor
need
improv
rnaibas
strategi
look
promis
nanoparticl
vector
ad
benefit
abl
imag
target
cell
tissu
like
mani
technic
hurdl
overcom
futur
result
improv
clinic
outcom
addit
insight
uniqu
properti
cancer
cell
continu
open
new
target
opportun
move
field
forward
